Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Merck
Medtronic

Last Updated: December 9, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MECASERMIN RINFABATE RECOMBINANT

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for mecasermin rinfabate recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01096784 ↗ IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity Completed Shire Phase 2 2010-06-18 To compare the severity of retinopathy of prematurity (ROP) among treated infants with an untreated control population, matched for gestational age at birth while confirming the dose of rhIGF-1/rhIGFBP-3 is safe and efficacious.
NCT02386839 ↗ Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP) Active, not recruiting Shire Phase 2 2015-03-26 The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (Section D) (NCT01096784).
NCT03253263 ↗ A Clinical Efficacy and Safety Study of SHP607 in Preventing Chronic Lung Disease in Extremely Premature Infants Active, not recruiting Shire Phase 2 2019-05-09 The purpose of this study is to determine if an investigational drug can reduce the burden of chronic lung disease in extremely premature babies through 12 months corrected age (CA), as compared to extremely premature babies receiving standard neonatal care alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for mecasermin rinfabate recombinant

Condition Name

Condition Name for mecasermin rinfabate recombinant
Intervention Trials
Retinopathy of Prematurity (ROP) 3
Bronchopulmonary Dysplasia 1
Chronic Lung Disease of Prematurity 1
Intraventricular Hemorrhage 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for mecasermin rinfabate recombinant
Intervention Trials
Retinopathy of Prematurity 3
Premature Birth 3
Retinal Diseases 2
Cerebral Hemorrhage 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for mecasermin rinfabate recombinant

Trials by Country

Trials by Country for mecasermin rinfabate recombinant
Location Trials
United States 30
Italy 6
Japan 5
United Kingdom 5
Sweden 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for mecasermin rinfabate recombinant
Location Trials
Wisconsin 3
North Carolina 3
Alabama 3
Oklahoma 3
West Virginia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for mecasermin rinfabate recombinant

Clinical Trial Phase

Clinical Trial Phase for mecasermin rinfabate recombinant
Clinical Trial Phase Trials
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for mecasermin rinfabate recombinant
Clinical Trial Phase Trials
Active, not recruiting 2
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for mecasermin rinfabate recombinant

Sponsor Name

Sponsor Name for mecasermin rinfabate recombinant
Sponsor Trials
Shire 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for mecasermin rinfabate recombinant
Sponsor Trials
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
AstraZeneca
Moodys
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.